{ "items" : [
    { "id" : "http://webisa.webdatacommons.org/127329319"
      "properties" : {
        "http://www.w3.org/1999/02/22-rdf-syntax-ns#type" : [ "http://www.w3.org/ns/prov#Entity" ] ,
        "http://www.w3.org/ns/prov#value" : [ "?? a broad range of regulatory issues in the pharmaceutical industry, including data exclusivity, biosimilars, orphan indications, labelling, off-label issues, the promotion of medicines and industry codes of practice such as the Association of the British Pharmaceutical Industry???s Code of Practice; and" ] ,
        "http://www.w3.org/ns/prov#wasQuotedFrom" : [ "pharmaceuticalethics.com" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/463601372"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/127329319"] } } }
